JCA NATIONAL IMPLEMENTATION · EU HTA

JCA implementation across Europe: National HTA assessment and procedural changes

Joint Clinical Assessment (JCA) provides a common European basis for the clinical assessment of new medicines. Member states consider JCA reports in their national HTA procedures, while therapeutic value and reimbursement and funding decisions remain subject to national requirements. This overview compares national assessment criteria and JCA-related procedural changes and identifies countries where JCA reports have been used in completed national assessments.

National HTA procedures and use of JCA reports across Europe

  • First national assessments using JCA reports completed: a completed national assessment demonstrably used a JCA report.
  • Use of JCA reports specified in national procedures: rules, dossier requirements, PICO processes or implementation steps are documented, but completed use is not yet verified.
  • National use of JCA reports not sufficiently documented: the reviewed sources do not support a reliable conclusion. This does not mean the regulation is not being implemented.

30 countries

National JCA implementation: 27 EU member states plus Norway, Iceland and Liechtenstein
Core of the national assessmentUse of JCA reports
AustriaAIHTA / SozialversicherungView country profile and sources →Clinical assessment in the Austrian care setting; for hospital medicines, evidence to inform national funding decisions.National PICO input is coordinated by care setting; AIHTA is developing Austria-specific fact sheets to contextualise JCA findings.Use of JCA reports specified in national procedures
BelgiumRIZIV / INAMIView country profile and sources →Therapeutic assessment within the national reimbursement process; a Belgian reimbursement application is still required.Clinical data already submitted for the JCA need not be resubmitted; national PICO consultation is provided for.Use of JCA reports specified in national procedures
BulgariaNCPRView country profile and sources →Clinical and pharmacoeconomic HTA supporting national pricing and listing decisions.National HTA rules explicitly provide for JCA; additional national information is required when a JCA report has been published.Use of JCA reports specified in national procedures
CroatiaHZJZView country profile and sources →Assessment of clinical effectiveness and safety alongside economic and other healthcare-system considerations.A national legal framework has been published; clinicians and patients contribute to national PICO input.Use of JCA reports specified in national procedures
CyprusGesundheitsministeriumThe national criteria for medicines HTA have not been established in sufficient detail from the reviewed authority sources.Participation in European HTA bodies is documented; national JCA dossier or assessment rules remain insufficiently evidenced.National use of JCA reports not sufficiently documented
CzechiaSÚKLView country profile and sources →National assessment for medicines reimbursement; detailed methodological requirements have not been fully verified here.SÚKL has documented national PICO input and cooperation with patient organisations; subsequent use of JCA reports remains unclear.Use of JCA reports specified in national procedures
DenmarkMedicinrådetView country profile and sources →Clinical benefit versus comparators relevant to Danish practice, together with cost-effectiveness and budget impact.The national dossier permits precise cross-references to JCA studies and analyses; additional local data and economic models remain necessary.Use of JCA reports specified in national procedures
EstoniaRavimiamet / TervisekassaClinical justification within the medicines reimbursement application; the detailed methodology has not been fully reviewed here.No specific national adjustment for JCA could be established from the reviewed authority sources.National use of JCA reports not sufficiently documented
FinlandFimeaView country profile and sources →Therapeutic and economic value of hospital medicines in the Finnish care setting.Where the PICO aligns, a national summary of the JCA may replace substantial clinical dossier content; economic assessment remains national.Use of JCA reports specified in national procedures
FranceHAS / CTView country profile and sources →The Transparency Committee assesses service médical rendu (SMR) and amélioration du service médical rendu (ASMR) for French reimbursement decisions.HAS prepares national PICO input and has piloted patient-expert involvement; the SMR/ASMR assessment remains separate.Use of JCA reports specified in national procedures
GermanyG-BA / IQWiGView country profile and sources →AMNOG early benefit assessment: added benefit versus the appropriate comparator therapy (zVT), subject to specific statutory rules for orphan medicines.The G-BA considered a JCA report in the completed tovorafenib assessment; the national added-benefit decision remains separate.First national assessments using JCA reports completed
GreeceGesundheitsministeriumNational medicines assessment and reimbursement; the specific assessment methods have not been fully verified here.An official implementation project and legislative changes have been reported; binding JCA dossier implications have not been established from the reviewed sources.National use of JCA reports not sufficiently documented
HungaryNEAKView country profile and sources →Health economic assessment using nationally relevant costs, health outcomes and uncertainty assumptions.National methodological guidance calls for a JCA aligned with the assessment scope when presenting relative efficacy and safety.Use of JCA reports specified in national procedures
IcelandEEA · LyfjastofnunThe national assessment criteria for medicines in the JCA context could not be established sufficiently from the reviewed sources.A notice on HTA preparation was identified but not fully reviewed; national JCA rules and EEA legal status remain open.National use of JCA reports not sufficiently documented
IrelandNCPEView country profile and sources →National Rapid Review of clinical and economic considerations to inform a reimbursement recommendation.NCPE used findings from the Itvisma JCA in a completed Rapid Review; this is not a final government reimbursement decision.First national assessments using JCA reports completed
ItalyAIFA / CSEView country profile and sources →Therapeutic need and added therapeutic value, alongside national pricing and reimbursement assessment.Where a JCA is available, specified clinical study annexes (C.4–C.6) are optional under the applicable conditions; Italian comparators remain relevant.Use of JCA reports specified in national procedures
LatviaZVAThe national medicines assessment criteria and reimbursement responsibilities are not sufficiently clarified by the reviewed sources.ZVA participation in European HTA bodies is documented, but national JCA dossier rules are not.National use of JCA reports not sufficiently documented
LiechtensteinEEA · Amt für GesundheitA distinct national medicines HTA framework for the JCA context has not been established from the sources.No specific national JCA integration has been evidenced; applicability through the EEA requires separate verification.National use of JCA reports not sufficiently documented
LithuaniaVVKTView country profile and sources →National health technology assessment; the specific criteria for medicines reimbursement are not sufficiently evidenced here.VVKT provided national PICO input for the 13 JCAs started in 2025; subsequent national use of the reports remains unclear.Use of JCA reports specified in national procedures
LuxembourgDirection de la santé / DPMThe national medicines assessment framework is not described in sufficient detail by the reviewed sources.An HTAR implementation review was documented in 2022; this does not establish current national JCA procedures.National use of JCA reports not sufficiently documented
MaltaHTA UnitClinical evidence supporting decisions on inclusion in the Government Formulary.The reviewed authority sources do not establish specific JCA-related changes to the listing process.National use of JCA reports not sufficiently documented
NetherlandsZorginstituut NederlandView country profile and sources →Assessment for the statutory basic benefits package, covering clinical, pharmacoeconomic and budget-impact considerations.National PICO consultation and use of JCA reports in the Dutch assessment process are described; the benefits-package decision remains national.Use of JCA reports specified in national procedures
NorwayEEA · DMPView country profile and sources →National metodevurdering to inform public funding of medicines, including health economic assessment.DMP has adapted dossier templates for JCA and offers early discussion of Norwegian PICO requirements and supplementary documentation.Use of JCA reports specified in national procedures
PolandAOTMiTView country profile and sources →National medicines reimbursement assessment; detailed clinical assessment criteria have not been fully verified here.National law provides for consideration of JCA within the reimbursement framework; specific submission implications remain to be clarified.Use of JCA reports specified in national procedures
PortugalINFARMED / CATSAdded therapeutic value (VTA) or therapeutic equivalence, together with economic advantage under SiNATS.Available INFARMED documents set out national assessment criteria but do not establish a specific JCA-related procedural change.National use of JCA reports not sufficiently documented
RomaniaANMDMRNational medicines HTA; specific criteria have not been sufficiently verified in the reviewed sources.Participation in the European HTA Coordination Group is documented, but national JCA procedural rules are not.National use of JCA reports not sufficiently documented
SlovakiaNIHONational medicines assessment against statutory criteria; the detailed methodology has not been fully reviewed here.NIHO confirms participation in European JCAs; the reviewed sources do not establish national dossier adjustments.National use of JCA reports not sufficiently documented
SloveniaGesundheitsministeriumAn HTA system for medical devices and in-vitro diagnostics is being developed; medicines HTA criteria are not sufficiently evidenced here.The identified implementation work concerns devices and IVDs; no specific rules for using medicinal-product JCAs have been established.National use of JCA reports not sufficiently documented
SpainAEMPS / Ministerio de SanidadView country profile and sources →National clinical and wider HTA assessment to support pricing, funding and reimbursement decisions.The 2026 HTA framework provides for JCA integration; additional dossier and procedural rules were still under consultation in November.Use of JCA reports specified in national procedures
SwedenTLV / SBUView country profile and sources →Relative clinical effect and cost-effectiveness in Swedish care, particularly for pricing and subsidy decisions.TLV and SBU have specified PICO coordination and use of JCA findings; initial national assessments involving JCA have started.Use of JCA reports specified in national procedures

Austria

Clinical assessment in the Austrian care setting; for hospital medicines, evidence to inform national funding decisions.

Use of JCA reports: National PICO input is coordinated by care setting; AIHTA is developing Austria-specific fact sheets to contextualise JCA findings.

View country profile and sources →

Belgium

Therapeutic assessment within the national reimbursement process; a Belgian reimbursement application is still required.

Use of JCA reports: Clinical data already submitted for the JCA need not be resubmitted; national PICO consultation is provided for.

View country profile and sources →

Bulgaria

Clinical and pharmacoeconomic HTA supporting national pricing and listing decisions.

Use of JCA reports: National HTA rules explicitly provide for JCA; additional national information is required when a JCA report has been published.

View country profile and sources →

Croatia

Assessment of clinical effectiveness and safety alongside economic and other healthcare-system considerations.

Use of JCA reports: A national legal framework has been published; clinicians and patients contribute to national PICO input.

View country profile and sources →

Cyprus

The national criteria for medicines HTA have not been established in sufficient detail from the reviewed authority sources.

Use of JCA reports: Participation in European HTA bodies is documented; national JCA dossier or assessment rules remain insufficiently evidenced.

Czechia

National assessment for medicines reimbursement; detailed methodological requirements have not been fully verified here.

Use of JCA reports: SÚKL has documented national PICO input and cooperation with patient organisations; subsequent use of JCA reports remains unclear.

View country profile and sources →

Denmark

Clinical benefit versus comparators relevant to Danish practice, together with cost-effectiveness and budget impact.

Use of JCA reports: The national dossier permits precise cross-references to JCA studies and analyses; additional local data and economic models remain necessary.

View country profile and sources →

Estonia

Clinical justification within the medicines reimbursement application; the detailed methodology has not been fully reviewed here.

Use of JCA reports: No specific national adjustment for JCA could be established from the reviewed authority sources.

Finland

Therapeutic and economic value of hospital medicines in the Finnish care setting.

Use of JCA reports: Where the PICO aligns, a national summary of the JCA may replace substantial clinical dossier content; economic assessment remains national.

View country profile and sources →

France

The Transparency Committee assesses service médical rendu (SMR) and amélioration du service médical rendu (ASMR) for French reimbursement decisions.

Use of JCA reports: HAS prepares national PICO input and has piloted patient-expert involvement; the SMR/ASMR assessment remains separate.

View country profile and sources →

Germany

AMNOG early benefit assessment: added benefit versus the appropriate comparator therapy (zVT), subject to specific statutory rules for orphan medicines.

Use of JCA reports: The G-BA considered a JCA report in the completed tovorafenib assessment; the national added-benefit decision remains separate.

View country profile and sources →

Greece

National medicines assessment and reimbursement; the specific assessment methods have not been fully verified here.

Use of JCA reports: An official implementation project and legislative changes have been reported; binding JCA dossier implications have not been established from the reviewed sources.

Hungary

Health economic assessment using nationally relevant costs, health outcomes and uncertainty assumptions.

Use of JCA reports: National methodological guidance calls for a JCA aligned with the assessment scope when presenting relative efficacy and safety.

View country profile and sources →

Iceland

The national assessment criteria for medicines in the JCA context could not be established sufficiently from the reviewed sources.

Use of JCA reports: A notice on HTA preparation was identified but not fully reviewed; national JCA rules and EEA legal status remain open.

Ireland

National Rapid Review of clinical and economic considerations to inform a reimbursement recommendation.

Use of JCA reports: NCPE used findings from the Itvisma JCA in a completed Rapid Review; this is not a final government reimbursement decision.

View country profile and sources →

Italy

Therapeutic need and added therapeutic value, alongside national pricing and reimbursement assessment.

Use of JCA reports: Where a JCA is available, specified clinical study annexes (C.4–C.6) are optional under the applicable conditions; Italian comparators remain relevant.

View country profile and sources →

Latvia

The national medicines assessment criteria and reimbursement responsibilities are not sufficiently clarified by the reviewed sources.

Use of JCA reports: ZVA participation in European HTA bodies is documented, but national JCA dossier rules are not.

Liechtenstein

A distinct national medicines HTA framework for the JCA context has not been established from the sources.

Use of JCA reports: No specific national JCA integration has been evidenced; applicability through the EEA requires separate verification.

Lithuania

National health technology assessment; the specific criteria for medicines reimbursement are not sufficiently evidenced here.

Use of JCA reports: VVKT provided national PICO input for the 13 JCAs started in 2025; subsequent national use of the reports remains unclear.

View country profile and sources →

Luxembourg

The national medicines assessment framework is not described in sufficient detail by the reviewed sources.

Use of JCA reports: An HTAR implementation review was documented in 2022; this does not establish current national JCA procedures.

Malta

Clinical evidence supporting decisions on inclusion in the Government Formulary.

Use of JCA reports: The reviewed authority sources do not establish specific JCA-related changes to the listing process.

Netherlands

Assessment for the statutory basic benefits package, covering clinical, pharmacoeconomic and budget-impact considerations.

Use of JCA reports: National PICO consultation and use of JCA reports in the Dutch assessment process are described; the benefits-package decision remains national.

View country profile and sources →

Norway

National metodevurdering to inform public funding of medicines, including health economic assessment.

Use of JCA reports: DMP has adapted dossier templates for JCA and offers early discussion of Norwegian PICO requirements and supplementary documentation.

View country profile and sources →

Poland

National medicines reimbursement assessment; detailed clinical assessment criteria have not been fully verified here.

Use of JCA reports: National law provides for consideration of JCA within the reimbursement framework; specific submission implications remain to be clarified.

View country profile and sources →

Portugal

Added therapeutic value (VTA) or therapeutic equivalence, together with economic advantage under SiNATS.

Use of JCA reports: Available INFARMED documents set out national assessment criteria but do not establish a specific JCA-related procedural change.

Romania

National medicines HTA; specific criteria have not been sufficiently verified in the reviewed sources.

Use of JCA reports: Participation in the European HTA Coordination Group is documented, but national JCA procedural rules are not.

Slovakia

National medicines assessment against statutory criteria; the detailed methodology has not been fully reviewed here.

Use of JCA reports: NIHO confirms participation in European JCAs; the reviewed sources do not establish national dossier adjustments.

Slovenia

An HTA system for medical devices and in-vitro diagnostics is being developed; medicines HTA criteria are not sufficiently evidenced here.

Use of JCA reports: The identified implementation work concerns devices and IVDs; no specific rules for using medicinal-product JCAs have been established.

Spain

National clinical and wider HTA assessment to support pricing, funding and reimbursement decisions.

Use of JCA reports: The 2026 HTA framework provides for JCA integration; additional dossier and procedural rules were still under consultation in November.

View country profile and sources →

Sweden

Relative clinical effect and cost-effectiveness in Swedish care, particularly for pricing and subsidy decisions.

Use of JCA reports: TLV and SBU have specified PICO coordination and use of JCA findings; initial national assessments involving JCA have started.

View country profile and sources →

PICO = population, intervention, comparator, outcomes. zVT = appropriate comparator (Germany).

EEA: European Economic Area state, not an EU member state. Whether and how the EU HTA Regulation applies there must be checked separately.

Research cut-off: 16 November 2026

EDITORIAL JCA IMPLEMENTATION

JCA in national HTA procedures: First assessments and changes to national requirements

Germany and Ireland have completed national medicines assessments using European JCA reports. Other countries have adapted dossier requirements, established national PICO processes or specified how European clinical findings will be used. The country analyses below explain these developments and their implications for national HTA requirements.

Tovorafenib: How the G-BA used the JCA in Germany’s AMNOG assessment

Ojemda · G-BA decision of 5 November 2026

  • First completed German AMNOG procedure involving a European JCA
  • National assessment retained the German benefit-assessment requirements
  • Magnitude of added benefit could not be quantified
Read analysis

The GBA considered the European JCA report in its assessment of tovorafenib. The clinical comparisons presented in the JCA did not automatically establish the magnitude of added benefit.

Tovorafenib’s orphan-drug status is decisive for the national assessment. Under the statutory conditions, added benefit is deemed established by marketing authorisation; the GBA assesses its magnitude using the available evidence. In its decision of 5 November 2026, the magnitude could not be quantified.

Considering a European JCA report does not automatically mean that its clinical analyses establish the magnitude of added benefit. The applicable AMNOG requirements remain decisive. The standard assessment against the appropriate comparator must be distinguished from the statutory rule for orphan drugs.

Primary source: G-BA, Tovorafenib benefit assessment decision, 05.11.2026

Itvisma: NCPE uses the JCA in an Irish rapid review

Intrathecal onasemnogene abeparvovec · July 2026

  • First documented national rapid review using a JCA
  • Comparative clinical findings from the European assessment considered
  • No full HTA or reimbursement at the submitted price recommended
Read analysis

The Irish rapid review of Itvisma provides an early example of European clinical findings being used in a national assessment. NCPE drew on relative effect estimates included in the JCA. A rapid review is not equivalent to a full health-economic assessment or a final public reimbursement decision. The case therefore demonstrates operational reuse of clinical evidence, not alignment of national funding outcomes. It does not establish which additional analyses will be required in every future Irish assessment.

Primary source: NCPE, First national assessment of a drug with an EU Joint Clinical Assessment, 17.07.2026

Denmark: Medicinrådet permits JCA cross-references in national submissions

Submission dossier · Version 2.2, June 2026

  • Clinical information already covered by the JCA need not be reproduced
  • Specific references to studies, endpoints and comparisons are envisaged
  • National economic models and budget impact analyses remain required
Read analysis

Denmark’s submission template sets out how European clinical findings may be reused in a national application. Precise references can replace duplication of studies and analyses already assessed in the JCA. Comparative effectiveness analyses should generally draw on the JCA analysis, although newer data cuts may require updates. Relevance to Danish populations and comparators must still be established. The change therefore reduces duplicate clinical documentation without removing national economic assessment. Conflicting official wording on the earliest submission point still requires verification.

Primary source: Medicinrådet, Submission dossier, v2.2, 30.06.2026

Italy: AIFA eases clinical study appendices where a JCA is available

HTA dossier guidance · Version 2.0, December 2025

  • Guidance explicitly reflects the EU HTA Regulation
  • Clinical study appendices C.4–C.6 are optional under specified JCA conditions
  • Comparators, therapeutic advantage and pricing remain national
Read analysis

AIFA has incorporated JCA-related provisions into its national pricing and reimbursement dossier. Under the conditions set out in the guidance, certain appendices covering controlled, uncontrolled and observational studies become optional. This is a limited documentation adjustment. The Italian submission must still address therapeutic need, nationally relevant comparators and additional therapeutic advantage. Budget impact and other economic considerations also remain part of the process. Making selected appendices optional should not be mistaken for removing the national clinical assessment or the national reimbursement dossier.

Primary source: AIFA, Linee guida compilazione del dossier, v2.0, 12/2025

Finland: Fimea sets out JCA use in hospital-medicine assessments

National guidance · April 2026

  • Specific submission requirements for medicines with a JCA published
  • A JCA summary can replace clinical sections where PICOs align
  • Finnish care context and health economics remain relevant
Read analysis

Fimea describes how European JCA findings feed into national assessments of hospital medicines. Preparatory material may be submitted before the European report is published, but the assessment depends on its availability. Where the JCA PICOs match Finland’s assessment question, the clinical component may largely rely on a national summary. Differences in populations or comparators can still require additional evidence. Economic assessment remains a national task. The announced start of an assessment of tarlatamab does not itself demonstrate a completed national application.

Primary source: Fimea, EU HTA hospital-only medicinal products, 24.04.2026

Belgium: RIZIV/INAMI links JCA references to national PICO scoping

National reimbursement assessment · Agency FAQ

  • JCA data already submitted at EU level need not be resubmitted
  • A 21-day national PICO consultation period is described
  • A Belgian reimbursement application remains necessary
Read analysis

Belgium connects the European clinical assessment with its national reimbursement application. Information already submitted for the JCA should not be sent again, although national additions may still be needed. RIZIV/INAMI also describes consultation with the competent reimbursement committee on Belgium’s PICO input and a 21-day period for gathering further expertise. The approach therefore addresses both early scoping and subsequent documentation. These procedural changes do not remove the national therapeutic and economic assessment.

Primary source: RIZIV/INAMI, FAQ Joint Clinical Assessment

Bulgaria: NCPR embeds JCA in national HTA rules

Procedural amendments · August 2025

  • National HTA provisions explicitly address JCA
  • National supplementary information is envisaged after JCA publication
  • Pharmacoeconomics and listing decisions remain national
Read analysis

Bulgaria has incorporated European clinical assessments into its national HTA provisions. Where a JCA has been published, the regulation provides for a national analysis of information not already covered by the European assessment. This is a concrete procedural link rather than a general statement of intent. National assessment continues to include clinical and pharmacoeconomic components as well as information required for pricing and reimbursement decisions. The reviewed sources do not yet document a completed Bulgarian case using a JCA.

Primary source: NCPR, national HTA regulation, amendments effective 12.08.2025

Netherlands: Zorginstituut Nederland connects JCA with package assessment

National reimbursement pathway · EU HTA guidance

  • Dutch stakeholders are consulted on PICO scoping
  • JCA reports can inform the national clinical assessment
  • Package decisions, health economics and budget impact remain national
Read analysis

The Netherlands links European clinical assessment with the decision on whether a medicine belongs in the insured basic benefits package. Dutch stakeholders can contribute relevant PICO questions during European scoping. Once available, JCA findings can be considered in the national process. Pharmacoeconomic and budget impact analyses may still be needed. In particular, the applicability of European comparisons to Dutch patient populations and clinical practice must be assessed. The JCA provides a shared clinical evidence base, while the package assessment remains a national responsibility.

Primary source: Zorginstituut Nederland, EU HTAR guidance/FAQ

Sweden: TLV and SBU detail national use of JCA reports

Joint implementation report · 2 November 2026

  • National PICO coordination and institutional cooperation developed
  • Use of European clinical findings in TLV procedures being prepared
  • First national procedures linked to JCA have started
Read analysis

TLV and SBU explain how Swedish participation in European scoping is coordinated and how JCA findings are intended to support national assessments. European clinical analyses may reduce duplication, but their relevance to the Swedish decision context still needs to be assessed. National responsibilities include comparator selection, assessment of relative clinical effects and health-economic analysis. The first procedures involving medicines with a JCA have started, but this does not yet demonstrate a completed national assessment documenting use of the report. Sweden is therefore in a concrete operational implementation phase.

Primary source: TLV/SBU, Fortsatt samordning av det nationella genomförandet av HTA-förordningen, 02.11.2026

Hungary: NEAK guidance establishes JCA results as clinical evidence for economic evaluations

Methodological guidance · 002324/2025

  • Relevant JCA reports envisaged as sources of clinical evidence
  • Relative efficacy and safety can inform national models
  • National cost-effectiveness assessment remains necessary
Read analysis

NEAK’s methodological guidance establishes a link between European JCA and Hungarian health-economic evaluation. Clinical effect estimates may be used when the JCA populations, interventions and comparators match the national assessment question. These findings must then be incorporated into a model reflecting national costs, health outcomes and uncertainty. The guidance provides a concrete methodological requirement, but the reviewed evidence does not yet demonstrate a completed Hungarian assessment using a JCA report.

Primary source: NEAK, health economic methodological guidance 002324/2025

Norway: DMP adapts national metodevurdering dossiers to JCA

Submission templates and PICO dialogue · 2026

  • National dossier templates adapted for medicines with a JCA
  • Early discussion of Norwegian PICO requirements available
  • Health economics and budget impact remain national
Read analysis

Norway’s DMP has adapted national submission templates to the European JCA framework. Developers can identify information already covered at EU level and discuss potential Norwegian additions early. National metodevurdering remains focused on domestic funding decisions, including clinical comparisons relevant to local practice, economic modelling and budget impact. The templates demonstrate operational preparation, not a completed national assessment with verified use of a JCA report. The legal applicability of the EU HTA framework in the EEA also requires separate consideration.

Primary source: DMP, national submission templates and EU HTA information, 2026

France: HAS involves patient experts in national JCA PICO scoping

PICO-FR · Pilot in 2025, continued in 2026

  • Patient experts involved in nine of 13 JCAs started in 2025
  • HAS extended the pilot in March 2026
  • SMR and ASMR remain distinct French assessment criteria
Read analysis

HAS piloted a structured approach to involving patient experts in France’s input to European JCA PICO scoping. Their contributions can inform the relevance of populations, comparators and outcomes at an early stage. Short European deadlines nevertheless limited participation in some procedures. The first pilot year does not establish how far patient input changed final French PICO proposals. The Commission de la transparence continues to assess service médical rendu (SMR) and amélioration du service médical rendu (ASMR). Participation in EU scoping does not replace this national appraisal.

Primary source: HAS, national PICO scoping patient participation report, 03/2026; CT annual report 2025

Austria: AIHTA develops national fact sheets for JCA findings

PICO coordination and Austrian contextualisation · 2026

  • National PICO input coordinated across care settings
  • Austria-specific fact sheets for JCA findings planned
  • National funding decisions remain separate
Read analysis

Austria is preparing European JCA findings for use in domestic decision-making. Coordination of national PICO questions reflects the different responsibilities in hospital and outpatient care. AIHTA describes clinical expert involvement for hospital medicines, while social insurance bodies contribute in the outpatient setting. Planned fact sheets will connect European clinical findings with Austrian care-context information. This may facilitate their use in national assessments, but the research programme does not establish routine use of the fact sheets in completed cases.

Primary source: AIHTA, PICO coordination methods; research programme 2026

Croatia: HZJZ involves clinicians and patients in JCA PICO scoping

National HTA framework · Implementing legislation 2025

  • National legal framework for EU HTA cooperation published
  • Clinicians and patients involved in national PICO input
  • Detailed JCA dossier rules not yet fully documented
Read analysis

Croatia established a national framework for EU HTA cooperation through legislation NN 40/2025. HZJZ describes the involvement of clinical experts and patients or carers in national PICO questions. This provides a concrete process for contributing to European scoping. Croatian HTA also considers clinical, economic, ethical and organisational dimensions. The documents reviewed do not yet provide a comprehensive medicines dossier guide for reusing JCA findings, nor do they demonstrate a completed national assessment using a JCA.

Primary source: HZJZ, EU HTA implementation information; NN 40/2025

Poland: AOTMiT documents the legal integration of JCA into reimbursement

National legislative amendments · September 2025

  • National provisions addressing JCA entered into force
  • European clinical assessments recognised in the reimbursement framework
  • Detailed national submission requirements still need verification
Read analysis

Poland has connected EU HTA cooperation to its reimbursement framework through national legislative amendments. AOTMiT describes the formal recognition of joint clinical assessments since September 2025. This establishes legal integration, but does not fully specify which clinical documents may be cross-referenced, which additional analyses are required or how national submission timelines align with JCA publication. A fuller operational assessment requires the current dossier rules and the first national assessment reports.

Primary source: AOTMiT, Wspólne oceny kliniczne – już formalnie w polskim prawie, 2025

Spain: Royal Decree 415/2026 establishes how JCA fits into the national HTA system

Royal Decree 415/2026 · Detailed rules under development

  • New national HTA framework adopted in 2026
  • Clinical assessment linked to European JCA
  • Detailed implementing rules still under consultation in November 2026
Read analysis

Spain reorganised its national health technology assessment system through Royal Decree 415/2026. AEMPS takes a central role in medicines assessment, with clinical and other national assessment dimensions addressed separately. On 12 November 2026, the Ministry of Health opened consultation on further rules covering dossier structure, economic analyses, stakeholder participation and report publication. Those detailed requirements had not yet been adopted at the research cut-off. Spain therefore has a defined legislative framework, while its operational rules remain under development.

Primary source: AEMPS, Real Decreto 415/2026; Ministerio de Sanidad consultation, 12.11.2026

Lithuania: VVKT submitted PICO input for all 13 JCAs started in 2025

Agency annual report 2025 · European scoping

  • National PICO input documented for 13 JCAs
  • Participation in early definition of European assessment questions
  • Subsequent national use of JCA reports not yet demonstrated
Read analysis

Lithuania participated systematically in European PICO scoping during the first year of EU HTA application. VVKT documents national input for all 13 JCAs initiated in 2025. This confirms participation in defining relevant populations, interventions, comparators and outcomes. The annual report does not yet sufficiently explain how published JCA reports will be used in Lithuanian reimbursement assessments. Scoping participation therefore should not be presented as evidence of specific dossier exemptions or completed national JCA-based assessments.

Primary source: VVKT, annual report 2025

Czechia: SÚKL documents PICO input and patient involvement in JCAs

Ten PICO contributions · Agency update December 2025

  • National PICO input reported for ten JCA procedures
  • Cooperation with patient organisations agreed for scoping
  • Later national use of JCA findings not yet sufficiently documented
Read analysis

SÚKL has developed Czech participation in European JCA scoping through PICO submissions and agreements with patient organisations. In December 2025 the agency reported ten national PICO contributions. Patient involvement may add perspectives on assessment questions relevant to Czechia. These steps concern the early European assessment phase, however. The sources do not yet fully establish which clinical findings can subsequently be reused in national medicines and reimbursement assessments or what additional analyses will be required.

Primary source: SÚKL, national PICO and patient involvement update, 03.12.2025